Fraunhofer Institute for Toxicology and Experimental MedicineHeaded by the institute director, Fraunhofer ITEM is organized in seven divisions, which have pooled their expertise in three business areas: Drug Development, Chemical Safety and Assessment, and Translational Biomedical Engineering. The Division of Cardiovascular Research of Prof. Thomas Thum, who has been managing Fraunhofer ITEM together with Prof. Norbert Krug since January 2021, is in the process of being established. Special expertise that is relevant for all business areas, namely in bioinformatics, comes from the corresponding project group. The Fraunhofer ITEM headquarters are in Hannover (Germany). The institute’s Division of Pharmaceutical Biotechnology has its facilities in Braunschweig on the “Science Campus Braunschweig-Süd”, and the Division of Personalized Tumor Therapy is based in Regensburg's BioPark.
Organizational structure of Fraunhofer ITEM
Facts and figures
At the end of 2020, 394 people were employed at Fraunhofer ITEM. The institute's sponsors include industry and commercial associations, the public sector, and the EU. The institute's budget in 2020 reached a level of approximately 37 million euros. Financing by acquired funding amounted to 67 percent. The share of industrial income in the institute’s budget was 44 percent. Investments of Fraunhofer ITEM amounted to approximately 1.6 million euros. For more details, please click on the below figures (as of April 2021).
Overview of Fraunhofer ITEM total headcount in the years 2017 to 2020
Overview of Fraunhofer ITEM total budget in the years 2017 to 2020
Overview of Fraunhofer ITEM external income in the years 2017 to 2020
About the Fraunhofer-Gesellschaft
The Fraunhofer-Gesellschaft is a recognized non-profit organization that takes its name from Joseph von Fraunhofer (1787–1826), the illustrious Munich researcher, inventor and entrepreneur.
The Fraunhofer-Gesellschaft, headquartered in Germany, is the world’s leading applied research organization. With its focus on developing key technologies that are vital for the future and enabling the commercial exploitation of this work by business and industry, Fraunhofer plays a central role in the innovation process. As a pioneer and catalyst for groundbreaking developments and scientific excellence, Fraunhofer helps shape society now and in the future. Founded in 1949, the Fraunhofer-Gesellschaft currently operates 75 institutes and research institutions throughout Germany. The majority of the organization’s 29,000 employees are qualified scientists and engineers, who work with an annual research budget of 2.8 billion euros. Of this sum, 2.4 billion euros are generated through contract research.
